Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug infused into brain arteries protect stroke patients during clot removal?

NCT ID NCT04664933

Symptom relief Sponsor: Hui-Sheng Chen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether giving a neuroprotective drug called 3-n-butylphthalide directly into the brain's arteries is safe and practical for people having a stroke caused by a blocked vessel. Participants are adults who are already scheduled for endovascular therapy, a procedure that threads a catheter through blood vessels to remove the clot. During and after that operation, the drug is infused into the artery for 16 to 24 hours. The study tracks serious complications and measures how well patients recover, using a disability scale, to see whether this added treatment deserves further testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3-n-butylphthalide, a neuroprotective drug given directly into the brain's arteries
What this could lead to
If it proves safe, this approach could add a brain-protecting step to standard stroke clot removal and might help more patients recover independence.
What could go wrong
This is a small, single-center safety study with no control group, so it cannot prove the drug helps. Delivering drugs into brain arteries carries risks like vessel injury or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years; 2. Acute ischemic stroke patients who is eligible for endovascular treatment; 3. Signed informed consent. Exclusion Criteria: 1. Modified Rankin Score \>2 caused by a history of prior stroke; 2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<80000/mm3); 3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); 5. Unsuitable for this clinical studies assessed by researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intravascular thrombosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intravascular thrombosis Mechanical thrombectomy Stroke, ischemic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Neurology, General Hospital of Northern Theater Command

    RECRUITING

    Shenyang, 110016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.